Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20984200 | 0.86 | PTGS2 (0.64) | PTGS2SMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL425146 | 0.84 | PTGS2 (0.62) | PTGS2SMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL4028705 | 0.82 | PTGS2 (0.60) | PTGS2SMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL5446840 | 0.82 | PTGS2 (0.59) | PTGS2SMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL28713032 | 0.81 | PTGS2 (0.58) | PTGS2SMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL18168759 | 0.80 | PTGS2 (1.00) | PTGS2SMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL2236676 | 0.80 | GAA (0.68) | PTGS2SMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL2887835 | 0.79 | PTGS2 (0.57) | PTGS2SMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL20711657 | 0.79 | PTGS2 (0.57) | PTGS2SMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL14518056 | 0.79 | L3MBTL1 (0.63) | PTGS2SMN1; SMN2KDM4EGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386984-B1 | HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS | UCB Biopharma SRL (BE) | 2021-08-11 | — | — | EP | disclosed |
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | Ichnos Sciences SA (CH) | 2020-11-03 | — | — | US | disclosed |
| US-10450320-B2 | Hexahydropyrazinotriazinone derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BE) | 2019-10-22 | — | — | US | disclosed |
| US-20190282548-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10391083-B2 | Triazolone compounds as MPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A (CH) | 2019-08-27 | — | — | US | disclosed |
| US-20180362532-A1 | Hexahydropyrazinotriazinone Derivatives as Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-12-20 | — | — | US | disclosed |
| EP-3386984-A1 | HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS | UCB Biopharma SPRL (BE) | 2018-10-17 | — | — | EP | disclosed |
| US-20180200229-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2018-07-19 | — | — | US | disclosed |
| US-9949955-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-04-24 | — | — | US | disclosed |
| WO-2017097871-A1 | HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2017-06-15 | — | — | WO | disclosed |
| US-20020016326-A1 | Nitrogen containing heteroaromatics with ortho-substituted P1's as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-07 | — | — | US | disclosed |
| US-6271237-B1 | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY | 2001-08-07 | — | — | US | disclosed |
| WO-1999032454-A9 | NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS | DU PONT PHARM CO (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1042299-A1 | NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032454-A1 | NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0374911-A1 | Water-soluble, fibre-reactive dyes, methods for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-06-27 | — | — | EP | disclosed |
| EP-0144766-B1 | REACTIVE DYES, THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1988-10-05 | — | — | EP | disclosed |
| EP-0159292-B1 | REACTIVE DYES, THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1988-01-07 | — | — | EP | disclosed |
| EP-0159292-A2 | Reactive dyes, their preparation and their use | CIBA-GEIGY AG (CH) | 1985-10-23 | — | — | EP | disclosed |
| EP-0144766-A2 | Reactive dyes, their preparation and their use | CIBA-GEIGY AG (CH) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016326-A1 | Nitrogen containing heteroaromatics with ortho-substituted P1's as factor Xa inhibitors | F12, F11, F2 | PTGS2 1688/4885SMN1; SMN2 1382/4885KDM4E 2758/4885 |
| US-20190282548-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | PTGS2 6/4885SMN1; SMN2 1312/4885KDM4E 3547/4885 |
| US-10391083-B2 | Triazolone compounds as MPGES-1 inhibitors | PTGES, PTGS1, PTGIS | PTGS2 6/4885SMN1; SMN2 1312/4885KDM4E 3547/4885 |
| US-20180200229-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | PTGS2 6/4885SMN1; SMN2 1312/4885KDM4E 3547/4885 |
| US-10450320-B2 | Hexahydropyrazinotriazinone derivatives as kinase inhibitors | PI4KA, PI4KB, PI4K2B | PTGS2 2321/4885SMN1; SMN2 4772/4885KDM4E 697/4885 |
| US-20180362532-A1 | Hexahydropyrazinotriazinone Derivatives as Kinase Inhibitors | PI4KA, PI4KB, PI4K2B | PTGS2 2321/4885SMN1; SMN2 4772/4885KDM4E 697/4885 |
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | PTGES, PTGS1, PTGIS | PTGS2 6/4885SMN1; SMN2 1312/4885KDM4E 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.